Goldberg Henrique, Mibielli Marco Antonio, Nunes Carlos Pereira, Goldberg Stephanie Wrobel, Buchman Luiz, Mezitis Spyros Ge, Rzetelna Helio, Oliveira Lisa, Geller Mauro, Wajnsztajn Fernanda
UERJ Medical School, Rio de Janeiro, Brazil.
UNIFESO Medical School, Teresópolis, Brazil.
J Pain Res. 2017 Feb 15;10:397-404. doi: 10.2147/JPR.S123045. eCollection 2017.
This paper reports on the results of treatment of compressive neuralgia using a combination of nucleotides (uridine triphosphate trisodium [UTP] and cytidine monophosphate disodium [CMP]) and vitamin B.
To assess the safety and efficacy of the combination of nucleotides (UTP and CMP) and vitamin B in patients presenting with neuralgia arising from neural compression associated with degenerative orthopedic alterations and trauma, and to compare these effects with isolated administration of vitamin B.
A randomized, double-blind, controlled trial, consisting of a 30-day oral treatment period: Group A (n=200) receiving nucleotides + vitamin B and Group B (n=200) receiving vitamin B alone. The primary study endpoint was the percentage of subjects presenting pain visual analog scale (VAS) scores ≤20 at end of study treatment period. Secondary study endpoints included the percentage of subjects presenting improvement ≥5 points on the patient functionality questionnaire (PFQ); percentage of subjects presenting pain reduction (reduction in VAS scores at study end in relation to pretreatment); and number of subjects presenting adverse events.
The results of this study showed a more expressive improvement in efficacy evaluations among subjects treated with the combination of nucleotides + vitamin B, with a statistically significant superiority of the combination in pain reduction (evidenced by VAS scores). There were adverse events in both treatment groups, but these were transitory and no severe adverse event was recorded during the study period. Safety parameters were maintained throughout the study in both treatment groups.
The combination of uridine, cytidine, and vitamin B was safe and effective in the treatment of neuralgias arising from neural compression associated with degenerative orthopedic alterations and trauma.
本文报道了使用核苷酸(三磷酸尿苷三钠[UTP]和单磷酸胞苷二钠[CMP])与维生素B联合治疗压迫性神经痛的结果。
评估核苷酸(UTP和CMP)与维生素B联合治疗因退行性骨科改变和创伤引起的神经压迫性神经痛患者的安全性和有效性,并将这些效果与单独使用维生素B进行比较。
一项随机、双盲、对照试验,包括为期30天的口服治疗期:A组(n = 200)接受核苷酸+维生素B,B组(n = 200)仅接受维生素B。主要研究终点是在研究治疗期结束时疼痛视觉模拟量表(VAS)评分≤20的受试者百分比。次要研究终点包括在患者功能问卷(PFQ)上改善≥5分的受试者百分比;疼痛减轻的受试者百分比(研究结束时VAS评分相对于治疗前的降低);以及出现不良事件的受试者数量。
本研究结果显示,在接受核苷酸+维生素B联合治疗的受试者中,疗效评估有更明显的改善,联合治疗在疼痛减轻方面具有统计学上的显著优势(由VAS评分证明)。两个治疗组均有不良事件,但这些都是短暂的,并且在研究期间未记录到严重不良事件。两个治疗组在整个研究过程中均维持了安全参数。
尿苷、胞苷和维生素B联合治疗因退行性骨科改变和创伤引起的神经压迫性神经痛是安全有效的。